For decades, the global pharmaceutical industry operated on a high-risk, high-reward model of chemical trial and error. You synthesized tens of thousands of compounds, pushed them through a decade of

When analysts discuss the artificial intelligence boom, the conversation reflexively defaults to the United States—to the algorithmic genius of OpenAI or the architectural dominance of Nvidia. But this narrative ignores

For the first half of this decade, humanoid robots were little more than viral marketing stunts—choreographed lab demonstrations designed to inflate venture capital valuations. In 2026, the era of the